Navigation Links
Sangamo BioSciences Announces Completion of Enrollment of Phase 2 Clinical Trial of ZFP Therapeutic for Diabetic Neuropathy
Date:12/4/2007

pletion of enrollment of the trial triggers a milestone payment from JDRF under this agreement.

About SB-509

SB-509 is a formulation of a zinc finger DNA-binding protein transcription factor (ZFP TF) designed to upregulate the expression of the gene encoding vascular endothelial growth factor (VEGF-A). Sangamo is currently evaluating this ZFP Therapeutic in a second ongoing Phase 2 clinical trial for the treatment of moderate to severe DN; plans to initiate a third Phase 2 trial to evaluate the effect of SB-509 on the mobilization of stem cells in subjects with DN; and has a preclinical program targeting spinal cord injury. Sangamo has also announced a new clinical program, the initiation of a Phase 2 clinical trial in Amyotrophic Lateral Sclerosis (Lou Gehrig's disease) in the first half of 2008.

Phase 2 study of SB-509 for mild to moderate DN

The clinical trial is a double-blind, placebo-controlled, repeat-dosing study designed to evaluate the clinical safety and clinical effects of repeat administration of SB-509 in diabetics with mild to moderate diabetic peripheral sensory motor neuropathy in the legs.

A total of 102 subjects have been enrolled into the trial. Subjects were randomized to one of two groups in a 2:1 ratio. The larger group is being treated by intramuscular injection of 60 mg of SB-509 (30 mg of SB-509 per leg) into the lower limb every 2 months. The remaining group is receiving an equal volume of placebo on the same schedule. Each subject will receive a total of three treatments (Day 0, 60 and 120). Subjects will receive injections in a distribution pattern that targets the skeletal muscle adjacent to the major peripheral nerves in the legs and feet.

The symptoms of diabetic peripheral neuropathy and any changes that occur during the trial will be evaluated based on neurological examination data, electrophysiological testing data, subject neurological questionnaire, and subject pain assessment. Investigat
'/>"/>

SOURCE Sangamo BioSciences, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Sangamo BioSciences and Sigma-Aldrich Announce Nature Biotechnology Study Demonstrating Zinc Finger Technology for Modification of Human Stem Cells
2. ImmuneRegen BioSciences Reports Material Transfer Agreement with VaxGen, Inc.
3. ImmuneRegen BioSciences, Inc. Demonstrates Radilex(TM) Increases Disease-Fighting White Blood Cells
4. Upstream Biosciences Acquires Innovative Platform Technology and Drug Candidates for Tropical Parasitic Diseases
5. Ardea Biosciences, Inc. Announces Completion of Phase 1 Clinical Trials of Novel Investigational HIV Drug RDEA806
6. Ardea Biosciences, Inc. Presents Results of Phase 1 Studies of RDEA806, a Novel NNRTI for HIV, at 47th ICAAC
7. Ardea Biosciences Lead MEK Inhibitor, RDEA119, to Enter Human Clinical Trials in Advanced Cancer Patients
8. Alacrity Biosciences Announces Positive Results from a Phase 2 Study of Its Dry Eye Treatment ALTY-0501
9. Regado Biosciences Initiates Phase IIa Clinical Study of REG1 Anticoagulation System
10. Regado Biosciences Presents Positive Data From REG1 Anticoagulation System Phase Ic Study at American Heart Association 2007 Scientific Sessions
11. Regado Biosciences Presents Early Stage Clinical Data for REG1 Anticoagulation System at American Heart Association 2007 Scientific Sessions
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/29/2014)... 2014 The Competitive Intelligence (CI) function is ... CI leaders who adjust will succeed, and those who ... Best Practices, LLC study CI leaders from 32 biopharmaceutical ... - Use secondary research whenever possible - it,s ... - Internal staff who are creative thinkers provide the ...
(Date:8/29/2014)... -- Pomerantz LLP has filed a class action lawsuit ... EDAP ) and certain of its officers.  The ... District of New York , and ... consisting of all persons or entities who purchased EDAP ... inclusive (the "Class Period"). This class action seeks to recover ...
(Date:8/29/2014)...   Mast Therapeutics, Inc. (NYSE MKT: ... Santosh Vetticaden, Chief Medical Officer and Senior Vice ... reasons, in mid-September.  Edwin L. Parsley , ... which Mast acquired earlier this year, will assume ... Chief Medical Officer.  Dr. Parsley previously was with ...
Breaking Medicine Technology:Using the Competitive Intelligence Function to Drive Better Business Decisions in the Pharmaceutical Sector 2SHAREHOLDER ALERT: Pomerantz Law Firm Announces the Filing of a Class Action against EDAP TMS S.A. and Certain Officers - EDAP 2SHAREHOLDER ALERT: Pomerantz Law Firm Announces the Filing of a Class Action against EDAP TMS S.A. and Certain Officers - EDAP 3Mast Therapeutics Announces Management Change 2Mast Therapeutics Announces Management Change 3Mast Therapeutics Announces Management Change 4
... announced the initiation of a landmark Phase 2 ... developed to improve neurological function in patients with ... In accordance with its internal focus on scientific ... at a peer-attended symposium at the American Spinal ...
... April 23, 2012 Medela convened the 7th ... on April 20-21, 2012. The annual event, attended ... lactation consultants, highlighted the latest insights into breastfeeding ... supporting breastfeeding women and their families through research ...
Cached Medicine Technology:Asubio Initiates Landmark Clinical Study in Spinal Cord Injury 2Asubio Initiates Landmark Clinical Study in Spinal Cord Injury 3Latest Findings in Breastfeeding Science Presented at Medela's 7th International Breastfeeding and Lactation Symposium 2Latest Findings in Breastfeeding Science Presented at Medela's 7th International Breastfeeding and Lactation Symposium 3
(Date:8/29/2014)... According to new research presented in a Science ... to Prescription Drug Misuse Among Young Adults (8/16), peer ... olds when it comes to prescription drug abuse. Researchers from ... the real problem which influences misuse of prescription drugs is ... of them to have fun with other using friends. Evidently ...
(Date:8/29/2014)... August 29, 2014 Healthpointe is proud ... Rodas. Dr. Rodas will be practicing out of Healthpointe’s ... a member of Healthpointe’s orthopedic team, Dr. ... medicine, and board-certified in occupational medicine. , Among ... as Medical Director of Raytheon, the world-class defense and ...
(Date:8/29/2014)... Charleston, SC (PRWEB) August 29, 2014 Highly regarded ... special reports on important hearing health topics. The four reports are ... The Secrets to Hearing Aid Success , ... Aid , Understanding Auditory Processing Disorder in Children ... 4 topics because there is a lot of confusion and misinformation ...
(Date:8/29/2014)... Mirada, CA (PRWEB) August 29, 2014 ... healthcare organizations, acquired a new medical center from LAXMed. The ... airport and less than 2 miles west of the 405 ... center within Southern California. The new LAX center is located ... 90045. , The new Healthpointe LAX office ...
(Date:8/29/2014)... New York, New York (PRWEB) August 29, 2014 ... died from cardiac arrest following a series of dialysis ... that alleges her death was the result of ... Liebhard LLP reports. The family’s lawsuit, which was file ... 2014, claims that the use of the products resulted ...
Breaking Medicine News(10 mins):Health News:Peer Pressure Irrelevant in Prescription Drug Abuse for Young Adults 2Health News:Peer Pressure Irrelevant in Prescription Drug Abuse for Young Adults 3Health News:Dr. Anthony G. Rodas Joins Healthpointe Team at LAX Office 2Health News:Charleston SC Audiologist, Dr. Mary Ann Larkin Authors Four New Special Reports on Important Hearing Healthcare Topics 2Health News:Charleston SC Audiologist, Dr. Mary Ann Larkin Authors Four New Special Reports on Important Hearing Healthcare Topics 3Health News:Healthpointe Obtains a New Medical Clinic in the LAX Area 2Health News:GranuFlo Lawsuit News: Family Alleges Woman’s Death Following Dialysis Was Caused by GranuFlo and NaturaLyte, Bernstein Liebhard LLP Reports 2Health News:GranuFlo Lawsuit News: Family Alleges Woman’s Death Following Dialysis Was Caused by GranuFlo and NaturaLyte, Bernstein Liebhard LLP Reports 3Health News:GranuFlo Lawsuit News: Family Alleges Woman’s Death Following Dialysis Was Caused by GranuFlo and NaturaLyte, Bernstein Liebhard LLP Reports 4
... Baby boomers are retiring healthy, financially secure and with a ... Lgar, baby boomers will remain among the most self-reliant generations ... independent their entire lives. They won,t stop being self-reliant when ... to back his hypothesis as he,s done at various national ...
... suffered side effects, including reduced strength after shots, study ... toxin, which smoothes facial wrinkles through injections of the ... "tennis elbow," a new study finds. , But the ... there,s a potentially nettlesome side effect, according to the ...
... , MONDAY, April 26 (HealthDay News) -- Children who ... likely to start drinking alcohol at an early age, ... middle-school children in New England and followed-up about two ... kids who said their parents never allowed them to ...
... The Baptist University of Hong Kong (HKBU) and Springer ... Essentials of Chinese Medicine. The three-volume English language set ... the Beijing University of Chinese Medicine and the School ... 14 distinguished scholars from Hong Kong, mainland China and ...
... Elsevier, the world-leading publisher of scientific, technical and ... release of a brand-new single volume comprehensive book ... by the internationally renowned cardiac surgeon and educator, ... the 90th Annual Meeting of the American Association ...
... ... market through its ActiveBase Security™ solution, today announced it has been included in the list ... Wagner, Joseph Feiman, Neil MacDonald, John Pescatore, Earl Perkins April 14, 2010, by Gartner Inc. ... Tel Aviv, Israel (PRWEB) ...
Cached Medicine News:Health News:Baby boomers aging to be self-reliant 2Health News:Botox Injections May Relieve Tennis Elbow Pain 2Health News:Watching R-Rated Movies May Lead to Early Alcohol Use 2Health News:Springer Asia launches Chinese medicine textbook series in English 2Health News:Elsevier launches Carpentier's reconstructive valve surgery book 2Health News:Leading Industry Analyst Firm Names ActiveBase "Cool Vendor" 2Health News:Leading Industry Analyst Firm Names ActiveBase "Cool Vendor" 3Health News:Leading Industry Analyst Firm Names ActiveBase "Cool Vendor" 4
The Victory single- and dual-chamber rate-responsive pacemakers from St. Jude Medical are advanced-feature systems, designed to save valuable clinic time, maximize patient safety, and provide other t...
... To help cardiologists meet the ... Toshiba introduces the high performance Infinix ... solutions combine easy-to-use controls, one-touch operations, ... to optimize workflow and allow physicians ...
Cardiac 5-Axis Bi-plane: Infinix CF-i/BP...
... on the promise of Flat Panel ... outstanding image quality, at lower doses, ... small devices and structures. The new ... at lower dose than other systems ...
Medicine Products: